InvestorsHub Logo
Followers 33
Posts 1496
Boards Moderated 0
Alias Born 12/06/2016

Re: None

Wednesday, 01/27/2021 1:27:26 PM

Wednesday, January 27, 2021 1:27:26 PM

Post# of 13741
Medolife's Therapeutic Scorpion Peptide Proves Successful in Treating COVID-19 Patients in Dominican Republic Study
Wed, January 27, 2021, 5:57 AM

BURBANK, CA / ACCESSWIRE / January 27, 2021 / Medolife Rx, Inc., ("Medolife") a majority owned subsidiary of Quanta, Inc. (OTC PINK:QNTA) today announced In a recent study, a total of 400 patients in the Dominican Republic - where, a majority tested positive for COVID-19, and a small portion were COVID-19 symptomatic even though they tested negative for COVID-19 - reported a 100 percent improvement in symptoms after being administered Escozine®. Many of the patients participating in the study reported severe COVID-19 symptoms, such as difficulty breathing, pain and high fever, which Escozine® was able to relieve within 5 days of treatment. Even patients under ventilators were discharged within days, thanks to this novel product. Located in Santo Domingo, Dominican Republic, The Cruz Jiminian Clinic has carried out this ongoing study since August 2020, and has reported 0 COVID-19 related deaths after the clinic began administering Escozine®. Escozine®, produced by Medolife Rx, Inc., ("Medolife"), is a therapeutic consisting of small molecule peptides derived from a specific species of scorpions, Rhopalurus princeps, endemic to the Dominican Republic. After the successful study, Escozine® is on fast-track to be registered with the Ministry of Health in the Dominican Republic in Q1 2021. Medolife also submitted the study data to the US FDA, which is currently under review for permission to repeat the clinical trial in the United States. In addition to supporting the recovery of COVID-19 patients, Escozine® was registered and certified for cancer treatment by the Ministry of Health in the Dominican Republic in 2010.

"The data proving the efficacy that Escozine has on a multitude of improved patient parameters is consistent with the rapid symptom relief I experienced while on site," said Dr. Annabelle Morgan, Cell and Developmental Biologist and one of Medolife's leading scientists. She noted, "What is even more astonishing is that 100% of patients tested negative for COVID-19 within 5-10 days of treatment."

Do your research, take your position, turn off the noise.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.